Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534797 | 0.98 | F2 (0.40) | F2ALOX5ALDH1A1PYGLITK | |
| SCHEMBL8773489 | 0.83 | ALDH1A1 (0.39) | F2ALDH1A1PYGLCCR5 | |
| SCHEMBL4929257 | 0.81 | ALDH1A1 (0.45) | F2ALDH1A1PYGLITKSLC6A2 | |
| SCHEMBL25804279 | 0.81 | ALDH1A1 (0.38) | F2ALDH1A1PYGLSLC6A2SLC6A4 | |
| SCHEMBL11556987 | 0.81 | ALDH1A1 (0.38) | F2ALDH1A1PYGLCCR5 | |
| SCHEMBL16316830 | 0.81 | ALDH1A1 (0.41) | F2ALDH1A1PYGLCCR5 | |
| SCHEMBL5475728 | 0.79 | PYGL (0.39) | F2ALDH1A1PYGLSLC6A2SLC6A4 | |
| SCHEMBL14276924 | 0.79 | PYGL (0.39) | F2ALDH1A1PYGLSLC6A2SLC6A4 | |
| SCHEMBL11006725 | 0.79 | ALDH1A1 (0.43) | F2ALDH1A1PYGLCCR5 | |
| SCHEMBL23795173 | 0.79 | CCR5 (0.36) | F2ALDH1A1PYGLSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348354-B2 | Cyclohexylurea compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| CN-1898317-A | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | GRUENENTHAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | OPRL1, OPRM1, OGFRL1 | F2 4784/4885ALOX5 2006/4885ALDH1A1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.